These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27906544)

  • 1. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease.
    Pflugfelder SC; Stern M; Zhang S; Shojaei A
    J Ocul Pharmacol Ther; 2017; 33(1):5-12. PubMed ID: 27906544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
    Paton DM
    Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
    Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME
    Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.
    Perez VL; Pflugfelder SC; Zhang S; Shojaei A; Haque R
    Ocul Surf; 2016 Apr; 14(2):207-15. PubMed ID: 26807723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multivalent ICAM-1 Binding Nanoparticle which Inhibits ICAM-1 and LFA-1 Interaction Represents a New Tool for the Investigation of Autoimmune-Mediated Dry Eye.
    Hsueh PY; Ju Y; Vega A; Edman MC; MacKay JA; Hamm-Alvarez SF
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
    Periman LM; Perez VL; Saban DR; Lin MC; Neri P
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues.
    Du G; Du W; An Y; Wang M; Hao F; Tong X; Gong Q; He X; Jiang H; He W; Zheng M; Zhang D
    Med Chem Res; 2022; 31(4):555-579. PubMed ID: 35194364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Force spectroscopy of the leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction.
    Zhang X; Wojcikiewicz E; Moy VT
    Biophys J; 2002 Oct; 83(4):2270-9. PubMed ID: 12324444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE].
    Erdinest N; Solomon A
    Harefuah; 2019 Feb; 158(2):130-135. PubMed ID: 30779493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells.
    Starling GC; McLellan AD; Egner W; Sorg RV; Fawcett J; Simmons DL; Hart DN
    Eur J Immunol; 1995 Sep; 25(9):2528-32. PubMed ID: 7589121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free ligand-binding assays for integrin LFA-1.
    Yuki K
    Methods Mol Biol; 2012; 757():73-8. PubMed ID: 21909907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low affinity of cell surface lymphocyte function-associated antigen-1 (LFA-1) generates selectivity for cell-cell interactions.
    Ganpule G; Knorr R; Miller JM; Carron CP; Dustin ML
    J Immunol; 1997 Sep; 159(6):2685-92. PubMed ID: 9300688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis.
    Watanabe T; Fan J
    Int J Cardiol; 1998 Oct; 66 Suppl 1():S45-53; discussion S55. PubMed ID: 9951802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A peptide derived from LFA-1 protein that modulates T-cell adhesion binds to soluble ICAM-1 protein.
    Jois SD; Teruna TJ
    J Biomol Struct Dyn; 2003 Apr; 20(5):635-44. PubMed ID: 12643766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of intercellular adhesion molecule-1 (ICAM-1) variants for antagonizing integrin lymphocyte function-associated antigen-1-dependent adhesion.
    Song G; Lazar GA; Kortemme T; Shimaoka M; Desjarlais JR; Baker D; Springer TA
    J Biol Chem; 2006 Feb; 281(8):5042-9. PubMed ID: 16354667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors.
    Anderson ME; Siahaan TJ
    Peptides; 2003 Mar; 24(3):487-501. PubMed ID: 12732350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of intercellular adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function-associated molecule-1 interaction with ICAM-1.
    Meyer DM; Dustin ML; Carron CP
    J Immunol; 1995 Oct; 155(7):3578-84. PubMed ID: 7561056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.